The synthetic oleanane triterpenoid CDDO-Me binds and inhibits pyruvate kinase M2

2020 ◽  
Vol 72 (3) ◽  
pp. 631-640 ◽  
Author(s):  
Iaci N. Soares ◽  
Raiane Viana ◽  
Charles B. Trelford ◽  
Eddie Chan ◽  
Boun Thai ◽  
...  
Author(s):  
Rajkumar Patle ◽  
Shital Shinde ◽  
Sagarkumar Patel ◽  
Rahul Maheshwari ◽  
Heena Jariyal ◽  
...  

2021 ◽  
Vol 30 ◽  
pp. 096368972110275
Author(s):  
Zhen Li ◽  
Lina Yang ◽  
Shuai Zhang ◽  
Jiaqi Song ◽  
Huanran Sun ◽  
...  

Energy metabolism programming is a hallmark of cancer, and serves as a potent target of cancer therapy. Valproic acid (VPA), a broad Class I histone deacetylases (HDACs) inhibitor, has been used as a therapeutic agent for cancer. However, the detail mechanism about the potential role of VPA on the Warburg effect in breast cancer remains unclear. In this study, we highlight that VPA significantly attenuates the Warburg effect by decreasing the expression of pyruvate kinase M2 isoform (PKM2), leading to inhibited cell proliferation and reduced colony formation in breast cancer MCF-7 and MDA-MB-231 cells. Mechanistically, Warburg effect suppression triggered by VPA was mediated by inactivation of ERK1/2 phosphorylation through reduced HDAC1 expression, resulting in suppressing breast cancer growth. In summary, we uncover a novel mechanism of VPA in regulating the Warburg effect which is essential for developing the effective approach in breast cancer therapy.


2016 ◽  
Vol 291 (19) ◽  
pp. 10307-10317 ◽  
Author(s):  
Kun Liu ◽  
Fanzhou Li ◽  
Haichao Han ◽  
Yue Chen ◽  
Zebin Mao ◽  
...  

2015 ◽  
Vol 459 (2) ◽  
pp. 327-332 ◽  
Author(s):  
Peng Yang ◽  
Zongwei Li ◽  
Yingying Wang ◽  
Lichao Zhang ◽  
Haili Wu ◽  
...  

2020 ◽  
Vol 3 (Supplement_1) ◽  
pp. i3-i4
Author(s):  
Corinne Beinat ◽  
Chirag Patel ◽  
Tom Haywood ◽  
Surya Murty ◽  
Lewis Naya ◽  
...  

Abstract BACKGROUND Pyruvate kinase M2 (PKM2) catalyzes the final step in glycolysis, a key process of cancer metabolism. PKM2 is preferentially expressed by glioblastoma (GBM) cells with minimal expression in healthy brain, making it an important biomarker of cancer glycolytic re-programming. We describe the bench-to-bedside development, validation, and translation of a novel positron emission tomography (PET) tracer to study PKM2 in GBM. Specifically, we evaluated 1-((2-fluoro-6-[18F]fluorophenyl)sulfonyl)-4-((4-methoxyphenyl)sulfonyl)piperazine ([18F]DASA-23) in cell culture, mouse models of GBM, healthy human volunteers, and GBM patients. METHODS [18F]DASA-23 was synthesized with a molar activity of 100.47 ± 29.58 GBq/µmol and radiochemical purity >95%. We performed initial testing of [18F]DASA-23 in GBM cell culture and human GBM xenografts implanted orthotopically into mice. Next we produced [18F]DASA-23 under current Good Manufacturing Practices United States Food and Drug Administration (FDA) oversight, and evaluated it in healthy volunteers and a pilot cohort of patients with gliomas. RESULTS In mouse imaging studies, [18F]DASA-23 clearly delineated the U87 GBM from the surrounding healthy brain tissue and had a tumor-to-brain ratio (TBR) of 3.6 ± 0.5. In human volunteers, [18F]DASA-23 crossed the intact blood-brain barrier and was rapidly cleared. In GBM patients, [18F]DASA-23 successfully outlined tumors visible on contrast-enhanced magnetic resonance imaging (MRI). The uptake of [18F]DASA-23 was markedly elevated in GBMs compared to normal brain, and it was able to identify a metabolic non-responder within 1-week of treatment initiation. CONCLUSION We developed and translated [18F]DASA-23 as a promising new tracer that demonstrated the visualization of aberrantly expressed PKM2 for the first time in human subjects. These encouraging results warrant further clinical evaluation of [18F]DASA-23 to assess its utility for imaging therapy-induced normalization of aberrant cancer metabolism.


Sign in / Sign up

Export Citation Format

Share Document